# Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)

> **NCT04906694** · PHASE2 · COMPLETED · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** COVI-DROPS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04906694
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2022-01-13
- **Final completion:** 2022-01-13
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04906694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04906694, "Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04906694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*